Medication info

Cabalin CR Extended-Release Tablet 75 mg (Pregabalin)

Prescription medicationTablet
Ingredient · strength
Pregabalin›42mg / 1 tablet
Manufacturer / importer
GL Pharm Tech Co., Ltd.
Appearance
This medicine is a white to yellowish-brown, rectangular, film-coated, extended-release three-layer tablet.
Packaging
30 tablets/box [(6 tablets/PTP x 5)]
Approval status
Active

MFDS item code 202401115 · Approved 2024.05.07

Summary

Main use
Treatment of peripheral neuropathic pain in adults
Who uses it
Adults · Children
Adult dosage
1. This medicine is administered once daily after the evening meal. The tablet must be swallowed whole and must not be split, crushed, or chewed. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see “2. Patients with Renal Impairment”). Adults: This medicine may be initiated at a dose of 1 tablet of 150 mg once daily. Based on the response and tolerability of each patient, the dose may be increased at weekly intervals to a maximum of 600 mg once daily. Discontinuation of treatment: Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually, with intervals of at least 1 week. 2. Patients with renal impairment This medicine (pregabalin 75mg) is for use only as the starting dose in patients with moderate renal impairment. Considering dose-dependent adverse reactions and the fact that pregabalin is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. Dose adjustment in patients with renal impairment is based on creatinine clearance (CLcr) [Table 1]. [Table 1] Dosage of this medicine based on renal function Creatinine clearance (CLcr)* (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), once daily Creatinine clearance (CLcr)* (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), once daily *Creatinine clearance (CLcr) can be estimated from serum creatinine (mg/dL) using the Cockcroft-Gault equation below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) / 72 x serum creatinine concentration (serum creatinine, mg/dL) *For women, multiply the result obtained from the above equation by 0.85. The safety and efficacy of this medicine have not been established in patients with severe renal impairment or end-stage renal disease with creatinine clearance (CLcr) less than 30 mL/min (see “11. Information for Healthcare Professionals,” “2) Pharmacokinetic Information” under “Precautions for Use”). 3. Patients with hepatic impairment The safety and efficacy of this medicine have not been established in patients with hepatic impairment. 5. Older adults (aged 65 years and older) The safety and efficacy of this medicine have not been established in older adults aged 65 years and older.
Children's dosage
4. Pediatric and adolescent patients The safety and efficacy of this drug have not been established in pediatric and adolescent patients under 19 years of age.

Ingredients

Manufacturer
GL Pharm Tech Co., Ltd.

Efficacy & effects

Treatment of peripheral neuropathic pain in adults

  • Peripheral neuropathic pain
View approved original text

This medication is used to effectively treat peripheral neuropathic pain in adults. It alleviates pain caused by nerve damage, thereby reducing the discomfort patients experience in their daily lives. It improves continuous pain to enhance quality of life. It safely supports the management of neuropathic pain and aids in the patient's recovery. This drug has a positive effect on the control of nerve-related pain.

Dosage and Administration

Adult dosage

1. This medicine is administered once daily after the evening meal. The tablet must be swallowed whole and must not be split, crushed, or chewed. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see “2. Patients with Renal Impairment”). Adults: This medicine may be initiated at a dose of 1 tablet of 150 mg once daily. Based on the response and tolerability of each patient, the dose may be increased at weekly intervals to a maximum of 600 mg once daily. Discontinuation of treatment: Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually, with intervals of at least 1 week. 2. Patients with renal impairment This medicine (pregabalin 75mg) is for use only as the starting dose in patients with moderate renal impairment. Considering dose-dependent adverse reactions and the fact that pregabalin is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. Dose adjustment in patients with renal impairment is based on creatinine clearance (CLcr) [Table 1]. [Table 1] Dosage of this medicine based on renal function Creatinine clearance (CLcr)* (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), once daily Creatinine clearance (CLcr)* (mL/min) ≥30-<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), once daily *Creatinine clearance (CLcr) can be estimated from serum creatinine (mg/dL) using the Cockcroft-Gault equation below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) / 72 x serum creatinine concentration (serum creatinine, mg/dL) *For women, multiply the result obtained from the above equation by 0.85. The safety and efficacy of this medicine have not been established in patients with severe renal impairment or end-stage renal disease with creatinine clearance (CLcr) less than 30 mL/min (see “11. Information for Healthcare Professionals,” “2) Pharmacokinetic Information” under “Precautions for Use”). 3. Patients with hepatic impairment The safety and efficacy of this medicine have not been established in patients with hepatic impairment. 5. Older adults (aged 65 years and older) The safety and efficacy of this medicine have not been established in older adults aged 65 years and older.

Children's dosage

4. Pediatric and adolescent patients The safety and efficacy of this drug have not been established in pediatric and adolescent patients under 19 years of age.

Precautions

This drug may increase the risk of suicidal thoughts or behaviors, so if mood or behavioral changes, symptoms of depression, etc., occur during treatment, consult a doctor immediately. Patients with hypersensitivity to this medication should not take it. Diabetes patients should be cautious as they may need to adjust their dose of blood sugar control medications due to weight gain. If allergic reactions such as angioedema occur, discontinue the medication immediately and inform medical personnel. Elderly patients should be particularly careful at the beginning of treatment due to risks of falls or injuries from dizziness or drowsiness. Visual changes such as blurred vision may occur, and such symptoms may improve after discontinuation of the medication. Withdrawal symptoms such as insomnia, headache, and anxiety may occur upon discontinuation, so the medication should be reduced gradually under a doctor's guidance. Due to the risk of drug abuse, patients with a history of substance abuse should be more cautious and report any abnormal behavior immediately. Patients with impaired kidney function may need dose adjustments. Patients with heart disease should be cautious as there may be a risk of congestive heart failure when taking this medication. Caution is advised if this drug is taken with opioid analgesics as it may increase central nervous system depressant effects, posing a risk of respiratory depression. It is best not to take the medication during pregnancy due to the risk of fetal malformation, and fertile women should use effective contraception. Women who are breastfeeding should discontinue nursing or consult a doctor while taking this medication as it may be passed into breast milk. Driving or operating dangerous machinery should be avoided until familiar with the effects of the drug, as dizziness and drowsiness may occur. In case of overdose, symptoms may include confusion, drowsiness, and seizures, and treatment such as hemodialysis may be necessary.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • angioedema
  • facial swelling
  • periorbital edema
  • upper respiratory tract edema
  • dizziness
  • drowsiness
  • loss of consciousness
Show 192 more
  • confusion
  • mental disorder
  • blurred vision
  • weight gain
  • constipation
  • dyspepsia
  • nausea
  • dry mouth
  • vomiting
  • peripheral edema
  • bradycardia
  • palpitations
  • pruritus
  • arthralgia
  • hypoglycemia
  • nasopharyngitis
  • hypertension
  • headache
  • stupor
  • hypersomnia
  • hypersomnia
  • increased appetite
  • decreased appetite
  • confusion
  • spatial disorientation
  • irritability
  • euphoria
  • decreased libido
  • insomnia
  • depersonalization
  • hyperesthesia
  • restlessness
  • agitation
  • mood swings
  • emotional lability
  • emotional elevation
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • loss of impulse control
  • apathy
  • ataxia
  • impaired coordination
  • balance disorder
  • memory loss
  • attention deficit
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbance
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorders
  • myoclonus
  • decreased reflexes
  • movement disorders
  • psychomotor agitation
  • position-related dizziness
  • hyperesthesia
  • burning sensation
  • activity tremor
  • syncope
  • confusion
  • hypomobility
  • olfactory disturbances
  • taste loss
  • writing disability
  • diplopia
  • vertigo
  • first-degree AV block
  • tachycardia
  • homogenous bradycardia
  • homogenous tachycardia
  • homogenous arrhythmia
  • hypotension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tension
  • nasal dryness
  • respiratory suppression
  • bloating
  • hypersalivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle spasms
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle cramps
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • reduced urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • breast pain
  • breast discharge
  • breast enlargement
  • gait abnormalities
  • falling
  • feeling intoxicated
  • sensory disturbances
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased blood potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hyperreactivity
  • allergic reactions
  • keratitis
  • congestive heart failure
  • pulmonary edema
  • tongue swelling
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis
  • slow movement
  • Guillain-Barré syndrome
  • discomfort in the head
  • palpitations
  • weakness
  • heat sensation
  • deep vein thrombosis
  • pneumonia
  • thalamic infarction
  • osteoarthritis
  • synovial cyst
  • anemia
  • oral sensory abnormalities
  • contusions
  • diabetic retinopathy
  • atrial fibrillation
  • hyperhidrosis
  • thyroid nodules
  • thyroid nodules
  • spinal canal stenosis
  • musculoskeletal discomfort
  • limb discomfort
  • abdominal pain
  • upper abdominal pain
  • eyelid swelling
  • cataracts
  • liver function abnormalities
  • increased blood alkaline phosphatase
  • ear disorders
  • mood disorders
  • coma
  • agitation
  • seizures
  • exacerbation of spasms

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it should be kept in a tightly sealed container. Additionally, it is recommended to store the drug at room temperature, not too hot or too cold, ideally between 1°C and 30°C.

Appearance and packaging

Appearance

This medicine is a white to yellowish-brown, rectangular, film-coated, extended-release three-layer tablet.

Package unit

30 tablets/box [(6 tablets/PTP x 5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.